03330nam a22003737a 4500
220706s20222022 xxu||||| |||| 00| 0 eng d
2666-6677
10.1016/j.ajpc.2022.100345 [doi]
PMC9097618 [pmc]
S2666-6677(22)00029-0 [pii]
Ovid MEDLINE(R)
35574517
The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
American Journal Of Preventive Cardiology. 10:100345, 2022 Jun.
Am J Prev Cardiol. 10:100345, 2022 Jun.
American journal of preventive cardiology
2022
FY2022
2022 Jun
epublish
PubMed-not-MEDLINE
2022-07-06
Conclusions: Treating all REDUCE-IT eligible US adults has substantial medication costs but could prevent a substantial number of ASCVD events and associated direct costs. Indirect cost savings by preventing events could outweigh much of the incurred direct costs. Copyright © 2022 The Author(s).
Methods: We derived REDUCE-IT eligible cohorts in (1) the National Health and Nutrition Examination Surveys (NHANES) 2009-2014 and (2) the Optum Research Database (ORD). Population sizes were obtained from NHANES and observed first event rates (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization, or coronary revascularization) were estimated from the ORD. Hazard ratios from REDUCE-IT USA estimated events prevented with IPE therapy. The National Inpatient Sample estimated event costs (facility and professional) and daily IPE treatment cost was approximated at
.59.
Objective: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; and (2) medication costs.
Results: We estimate 3.6 million US adults to be REDUCE-IT eligible, and the observed five-year first event rate without IPE of 19.0% (95% confidence interval [CI] 16.6%-19.5%) could be lowered to 13.1% (95% CI 12.8%-13.5%) with five years of IPE treatment, preventing 212,000 (uncertainty range 163,000-262,000) events. We projected the annual IPE treatment cost for all eligible persons to be
.0 billion (95% CI
.7-
.5 billion), but saving
.8 billion annually due to first events prevented (net annual cost
.3 billion). The total five-year event rate (first and recurrent) could be reduced from 42.5% (95% CI 39.6%-45.4%) to 28.9% (95% CI 26.9-30.9%) with five years of IPE therapy, preventing 490,000 (uncertainty range 370,000-609,000) events (net annual cost
.6 billion).
English
MedStar Health Research Institute
Journal Article
Weintraub, William S
Abrahamson D, Andrade KE, Bhatt DL, Bress AP, Derington CG, Fan W, Herrick JS, Jiao L, Johnson J, Philip S, Weintraub WS, Wong ND
https://dx.doi.org/10.1016/j.ajpc.2022.100345
https://dx.doi.org/10.1016/j.ajpc.2022.100345
ART
Article
0
0
0
0
Article
authcat
authcat
2022-07-06
0
35574517
35574517
2022-07-06
2022-07-06
ART
435
435